How long does it take for Tarlatamab-Imdelltra to work?

Tarlatamab-Imdelltra is a DLL3-targeted bispecific T cell redirecting antibody. Its anti-tumor mechanism is to simultaneously bind to tumor cell DLL3 antigen and CD3 molecules of patient T cells, thereby directly recruiting T cells into the tumor microenvironment, thereby mediating the rapid killing of cancer cells. This direct immune redirection effect means that the drug can initiate an immune response in a shorter period of time in the body, but the specific onset of effect varies depending on individual patient differences, tumor load, immune system status, and combination treatment options.

In clinical trials, some patients with small cell lung cancer (ES-SCLC) who received talatumumab could observe a decrease in tumor markers or an improvement in imaging tumor burden within a few weeks of the first dose, suggesting that the T cell-mediated killing effect can appear earlier. However, clinically it is generally recommended to conduct the first efficacy assessment at least 4 to 6 weeks after drug administration to obtain relatively stable and comparable changes in imaging or biomarkers. In addition, some patients may require multiple consecutive doses to obtain optimal efficacy, because the effect of bispecific antibodies not only relies on initial T cell activation, but also requires continued maintenance of T cell activity and immune responses in the tumor microenvironment.

The rapid onset of action of talatumumab does not mean that all patients can achieve significant clinical improvement in the short term. Efficacy evaluation is usually comprehensively evaluated by combining imaging examinations, tumor markers, and changes in clinical symptoms. In clinical practice, doctors will closely monitor patients' hematological indicators, immune-related side effects, and changes in tumor load to determine treatment response and optimize dosing regimens. For some patients with severe illness or large tumor burden, the onset of effect may be relatively prolonged, but long-term use can usually maintain the immune killing effect stably and improve the disease control rate.

Reference materials:https://www.drugs.com/mtm/tarlatamab.html